{"id":170617,"date":"2023-08-26T03:24:45","date_gmt":"2023-08-26T08:24:45","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2023\/08\/enhanced-efficacy-for-next-gen-antibody-therapies"},"modified":"2023-08-26T03:24:45","modified_gmt":"2023-08-26T08:24:45","slug":"enhanced-efficacy-for-next-gen-antibody-therapies","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2023\/08\/enhanced-efficacy-for-next-gen-antibody-therapies","title":{"rendered":"Enhanced Efficacy for Next-Gen Antibody Therapies"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/enhanced-efficacy-for-next-gen-antibody-therapies.jpg\"><\/a><\/p>\n<p>The company achieved proof-of-concept with trastuzumab, an anti-HER2 antibody. Preclinical studies show Multilink increases cytotoxicity and improves tumor regression.<\/p>\n<p>In mouse studies, tumor volume after 49 days was approximately half its original size with Trastuzumab Multilink (T-Multilink) with mertansine (DM1), but had grown four-fold when treated with the same compound without the linker. Comparable studies with T-Multilink-auristatin F showed complete tumor regression by about day 25, while treatment without the linker allowed the tumor to approximately triple in size.<\/p>\n<p>\u201cMultilink is a powerful technology to tackle cancers with low antigen expression,\u201d Marx says. Debiopharm is using it to develop \u201cnovel, potent, stable, and safe ADCs for various antibodies.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The company achieved proof-of-concept with trastuzumab, an anti-HER2 antibody. Preclinical studies show Multilink increases cytotoxicity and improves tumor regression. In mouse studies, tumor volume after 49 days was approximately half its original size with Trastuzumab Multilink (T-Multilink) with mertansine (DM1), but had grown four-fold when treated with the same compound without the linker. Comparable studies [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-170617","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/170617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=170617"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/170617\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=170617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=170617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=170617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}